FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Vaccine makers settle France's H1N1 bill

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

A newspaper has reported that France has struck a deal to pay several large vaccine makers just 16 percent of the amount it had contracted to pay after canceling a huge order of swine flu vaccine. According to Le Figaro, Novartis, GlaxoSmithKline and Sanofi will get €48 million in payment for €358 million of vaccine that the country had ordered and then cancelled. GSK will face the steepest loss from the cancellation. A number of European countries were stuck with large supplies of H1N1 vaccine after the pandemic turned out to be milder than anticipated and a huge portion of their populations shunned the jab. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Novartis   GlaxoSmithKline   Sanofi-Aventis   swine flu   France